Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Nektar Therapeutics (NKTR) had Return on Equity of -370.37% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$10.46M |
|
$-50.88M |
|
-- |
|
$10.46M |
|
$54.99M |
|
$-44.53M |
|
$-1.83M |
|
$-46.37M |
|
$-46.37M |
|
$-46.42M |
|
$-50.88M |
|
$-50.88M |
|
$-46.42M |
|
$-44.53M |
|
$-45.43M |
|
210.92M |
|
210.92M |
|
$-0.24 |
|
$-0.24 |
|
| Balance Sheet Financials | |
$229.91M |
|
$3.16M |
|
$26.33M |
|
$256.24M |
|
$70.93M |
|
-- |
|
$171.57M |
|
$242.50M |
|
$13.74M |
|
$13.74M |
|
$13.74M |
|
186.10M |
|
| Cash Flow Statement Financials | |
$-49.05M |
|
$43.69M |
|
$0.01M |
|
$44.25M |
|
$38.89M |
|
$-5.36M |
|
$3.90M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.24 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-425.76% |
|
-425.76% |
|
-- |
|
-443.30% |
|
-486.44% |
|
$-49.05M |
|
-- |
|
-- |
|
-- |
|
0.04 |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-370.37% |
-370.37% |
|
-19.86% |
|
-370.37% |
|
$0.07 |
|
$-0.23 |
|
$-0.23 |
|